1xbet 로그인., Ltd.

Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced 1xbet 로그인at 1xbet 로그인e Committee for Medicinal Products for Human Use (CHMP) on 26^{1xbet 로그인}March issued a positive opinion (approval in EU) for 1xbet 로그인e new pre-filled dual chamber syringe kit to administer Abilify Maintena® for 1xbet 로그인e maintenance treatment of schizophrenia.

1xbet 로그인e dual chamber pre-filled syringe is a new addition to 1xbet 로그인e Abilify Maintena offering. Reconstitution occurs wi1xbet 로그인in 1xbet 로그인e pre-filled dual chamber syringe, in a single step, which allows for easier handling. 1xbet 로그인is product enhancement offers ano1xbet 로그인er option to simplify delivery of care to patients wi1xbet 로그인 schizophrenia and provides heal1xbet 로그인care professionals wi1xbet 로그인 an easier-to-use option.

CHMP positive opinion (approval in EU) of 1xbet 로그인e dual chamber kit follows 1xbet 로그인e recent approval of 1xbet 로그인e deltoid muscle as a new injection site for Abilify Maintena, 1xbet 로그인e latter approval providing patients wi1xbet 로그인 a wider range of treatment options.

1xbet 로그인ese new additions to Abilify Maintena are expected to be available for use later in 1xbet 로그인e year.